<DOC>
	<DOCNO>NCT00829257</DOCNO>
	<brief_summary>The purpose study establish whether addition extra-fine particle steroid inhaler achieve additional suppression small airway inflammation add 'standard ' Fluticasone/Salmeterol combination therapy refractory asthma .</brief_summary>
	<brief_title>Additive Effects QVAR ( Seretide ) Surrogate Markers Airway Inflammation Refractory Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Refractory , nonsmoking asthmatic FEV1 les 80 % predict RV great 100 % predict CANO great 3ppb step 1000Âµg fluticasone per day , without additional asthma medication . Informed consent ability perform exhale nitric oxide assessment . Participants must great 500mcg fluticasone per day enter dose ramp runin . Recent respiratory infection oral steroid use . Pregnancy lactation . Known suspected contraindication IMP 's . CANO le 3ppb , FEV1 great 80 % RV le 100 % postoptimisation visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>